---
schema_version: "secwatch.filing_event.v1"
accession: "0001839882-23-022729"
form_type: "8-K"
ticker: null
cik: "0000887247"
company_name: "DMK PHARMACEUTICALS Corp"
filed_at: "2023-08-29T23:59:59+00:00"
generated_at: "2026-06-11T02:42:07.074439+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Adamis Pharmaceuticals enters CEO employment agreement with Ebrahim Versi, M.D., Ph.D.

## Summary
- Base salary of $585K/year effective from May 25, 2023 merger closing; lump sum retroactive payment for prior period.
- Target annual bonus of 60% of base salary; eligibility for discretionary bonuses and equity awards.
- Termination without cause or for good reason yields 18 months salary continuation (or lump sum if within 12 months before/after change in control).
- Change in control triggers full vesting acceleration of all stock options and RSUs.
- Severance includes COBRA premium coverage for up to 18 months, subject to release.

## SEC filing metadata
- accession: 0001839882-23-022729
- form_type: 8-K
- cik: 0000887247
- company_name: DMK PHARMACEUTICALS Corp
- filed_at: 2023-08-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/887247/000183988223022729/0001839882-23-022729-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/887247/000183988223022729/admp-8k_082323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001839882-23-022729
- JSON: https://secwatch.observer/filing/0001839882-23-022729.json
- Plain text: https://secwatch.observer/filing/0001839882-23-022729.txt

## Key facts
- Executive change
  Ebrahim Versi, M.D., Ph.D. was appointed as Chief Executive Officer and Chairman of the Board at DMK PHARMACEUTICALS Corp.
  - Action: appointed
  - Role: Chief Executive Officer and Chairman of the Board
  source text: On August 23, 2023, Adamis Pharmaceuticals Corporation (the “Company”) entered into an employment agreement with Ebrahim Versi, M.D., Ph.D., who became the Company’s Chief Executive Officer and Chairman of the board of directors of the Company (the “Board”) in connection with the closing of the merger transaction (the “Merger”) with DMK Pharmaceuticals Corporation effective May 25, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/887247/000183988223022729/0001839882-23-022729-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.